106 results about "Antiantibody" patented technology

The present invention provides methods for treating atopic dermatitis (AD). Also provided are methods for improving one or more AD-associated parameter(s), and methods for decreasing the level of at least one AD-associated biomarker in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.

The present invention includes antibodies or antigen-binding fragments thereof that specifically bind to TMPRSS2, and methods of using such antibodies and fragments to treat or prevent viral infection (eg, influenza virus infection). [Selected Figure] Figure 2

The invention relates to stable formulations comprising an anti-CLEVER-1 antibody or antigen binding fragment(s) thereof, a buffer and a stabilizing agent. The present invention further relates to stable formulations of an anti-CLEVER-1 antibody or antigen binding fragments thereof for use in treatment of various diseases and disorders.

Provided in the present invention is an anti-PVRIG antibody or an antigen-binding fragment thereof, wherein the antibody comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises HCDR1 to HCDR3, and the light chain variable region comprises LCDR1 to LCDR3. In the heavy chain variable region of the antibody, the amino acid sequence of HCDR1 is as shown in SEQ ID NO: 9, the amino acid sequence of HCDR2 is as shown in SEQ ID NO: 10, and the amino acid sequence of HCDR3 is as shown in SEQ ID NO: 11; and in the light chain variable region of the antibody, the amino acid sequence of LCDR1 is as shown in SEQ ID NO: 12, the amino acid sequence of LCDR2 is as shown in SEQ ID NO: 13, and the amino acid sequence of LCDR3 is as shown in SEQ ID NO: 14.

The present invention provides an anti-CD39 antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition comprising the conjugate or the pharmaceutically acceptable salt or solvate thereof, and use thereof as an anti-cancer drug, particularly use thereof in the preparation of a medicament for treating a CD39-mediated disease or disorder. The anti-CD39 antibody-drug conjugate provided by the present application significantly improves the effects and in-vivolin-vitro tumor-killing activity of cytotoxin drugs.

Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates) thereof that bind PSMA, as well as STING agonist linker-drug conjugates and preparation thereof, are disclosed. The disclosure further relates to methods and compositions for use in the treatment of, e.g., cancer by administering the compositions provided herein.

The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and / or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

One method for treating Crohn's disease in a patient involves administering a specific antibody against IL-23, for example, guselkumab, in an initial subcutaneous dose and subsequent subcutaneous doses so that the patient responds to the antibody and meets one or more of the clinical objectives.

The present application relates to the field of medical detection, in particular to a detection reagent, a detection kit and a detection method of amyloid aggregates. The present application provides a seed amplification test method of pathological alpha-synuclein aggregates, which coats or fixes specific anti-alpha-Syn antibodies on the bottom and side of an enzyme-labeled plate, captures pathological alpha-Syn aggregates in the sample, washes off unbound alpha-Syn or other substances, effectively removes various interference amplification factors in the sample, and incubates and amplifies in a buffer containing alpha-Syn monomers in a vibration-intermittent vibration cycle. In the initial stage of SAA amplification, the pathological alpha-Syn aggregates as seeds are adsorbed to the interface between the solid phase and the liquid phase with the maximum shear stress, greatly increasing the alpha-Syn aggregation efficiency, shortening the lag time in the initial stage, greatly shortening the amplification time, and solving the problems existing in the current alpha-Syn-SAA test.

The invention provides stable lyophilized formulation of anti-α4ß7 antibody comprising buffer, sugar, bulking agent, viscosity reducer, antioxidant and surfactant.

Provided are a pharmaceutical composition containing an anti-Nectin-4 antibody drug conjugate and a use thereof. The provided pharmaceutical composition has good stability.

The present invention provides antibodies that bind to human CEACAM5 protein, as well as isolated nucleic acids and host cells comprising sequences encoding the antibodies. The present invention also provides immunoconjugates comprising the antibodies linked to growth inhibitory agents, and pharmaceutical compositions comprising the antibodies or immunoconjugates of the present invention. The present invention also provides uses of the antibodies, immunoconjugates, and pharmaceutical compositions of the present invention for the treatment or diagnosis of cancer.

The application discloses a urine small extracellular vesicle PLA2R1 membrane protein detection method for distinguishing membranous nephropathy, and belongs to the technical field of biomedical detection. The detection method comprises the following steps: preparing an anti-CD63 antibody surface fixed plasmonic metasurface sensing chip to directly capture small extracellular vesicles in urine; preparing an anti-PLA2R1 antibody modified biofunctionalized gold nanoparticle complex to specifically combine with the PLA2R1 membrane protein on the surface of the small extracellular vesicles; detecting the reflection spectrum of the chip after antibody fixation and gold nanoparticle combination through a spectrometer with an integrated optical fiber probe; calculating the resonance wavelength shift amount; measuring the expression level of the PLA2R1 membrane protein; and realizing accurate distinction of healthy people, membranous nephropathy gray area and confirmed patients. The non-invasive detection method is simple in operation and rapid in detection, the sensitivity and the specificity are improved by means of the gold nanoparticle signal amplification effect, and is suitable for large-scale clinical screening and early diagnosis.

Disclosed are antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates (ADCs), including those that include splicing modulators) that bind to BCMA. The disclosure further relates to methods and compositions for use in treating cancer by administering the compositions provided herein.

A conjugate having stability improved more than conventional conjugates without impairing the efficacy is provided by the present invention. The conjugate of the present invention is a conjugate of an anti-EGFR antibody site-specifically modified with a peptide and a chelating agent, wherein the chelating agent is chelated with a metal radionuclide, the peptide and the chelating agent are linked by a linker (L), and the linker (L) does not contain a thiourea bond.

Methods for the clinical treatment of neuromyelitis optica spectrum disorder (NMOSD) using anti-C5 antibodies or antigen-binding fragments thereof are provided. The present disclosure provides methods for treating neuromyelitis optica spectrum disorder (NMOSD) in a subject in need thereof by administering an antibody that specifically binds to complement component 5 (C5). In certain embodiments, the antibody that specifically binds C5 reduces the rate at which C5 is cleaved into C5a and C5b in vivo. In other embodiments, the antibody that specifically binds C5 binds to one or both of the C5a and / or C5b fragments. In any of these embodiments, the antibody that specifically binds C5 reduces the complement cascade at C5, thereby reducing the release of proinflammatory mediators and the formation of cytolytic pores.

The present invention pertains to an optical nerve protecting agent containing an anti-low density lipoprotein receptor-related protein 1 (LRP1) antibody or fragment of the anti-LRP1 antibody.

The invention relates to prostate specific membrane antigen antibodies (anti-PSMA) and anti-PSMA antibody drug conjugates (ADCs). The invention provides a method for treating a subject using anti-PSMA ADCs in inhibiting, preventing or treating PSMA-related diseases or cancers, including prostate cancer. The disclosure also provides pharmaceutical compositions containing anti-PSMA ADCs suitable for administration to human subjects.

The present disclosure relates to generally to methods of ameliorating or treating the neurological effects of microglial activation and methods of ameliorating or treating specific diseases that affect the central nervous system (CNS) by administering an anti-CD3 antibody in combination with a GLP-1 agonist.

The present invention provides pharmaceutical formulation comprising a human antibody that specifically binds to human proprotein convertase subtilisin / kexin type 9 (PCSK9). The formulation may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulation o f the present invention exhibits a substantial degree o f antibody stability after storage for several months.

The application provides a biomarker for assisting in diagnosing systemic lupus erythematosus and application thereof, proves that 15(S)-HETE has good diagnostic efficiency for systemic lupus erythematosus, and the diagnostic efficiency is improved after 15(S)-HETE is combined with anti-dsDNA antibody or anti-Smith antibody, has good diagnostic efficiency for systemic lupus erythematosus with negative specific autoantibody, and 15(S)-HETE can also reflect the disease activity of systemic lupus erythematosus.

A pharmaceutical composition characterized in that a combination of an (anti-HER2 antibody)-drug conjugate and a HER dimerization inhibitor is administered, in which the (anti-HER2 antibody)-drug conjugate comprises a drug linker represented by the formula shown below (wherein A represents a binding position to an anti-HER2 antibody) and an anti-HER2 antibody bonded to each other through a thioether bond; and / or a treatment method characterized in that a combination of the (anti-HER2 antibody)-drug conjugate and the HER dimerization inhibitor is administered to an individual.

Provided herein are anti-IL5R antibody formulations containing an amount of surfactant below critical micelle concentration (CMC) of the surfactant and methods of using such formulations.

Provided herein are pharmaceutical compositions and formulations of a conjugate comprising a first protein, such as an anti-VEGF antibody, conjugated to a phosphorylcholine-containing polymer, and a second protein not conjugated to the phosphorylcholine-containing polymer. The second protein may be the same as the first protein or may be different from the first protein. In some embodiments, the pH of the formulation is different from the isoelectric point (pI) of the second protein to prevent or reduce the turbidity of the formulation. Also provided are methods of making the formulations, methods of use thereof, and kits having pre-filled syringes containing the formulations.

The present disclosure provides ALK7 binding proteins, such as anti-ALK7 antibodies and compositions, and methods for making the same. In certain embodiments, the ALK7 binding proteins inhibit or antagonize ALK7 activity. Further, the present disclosure provides compositions and methods for diagnosing and treating the following diseases: overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and associated conditions thereof; metabolic disorders, and other diseases or conditions that can be treated, prevented, or ameliorated by targeting ALK7.